Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy

Cristina M. Contreras, Esra A. Akbay, Teresa D. Gallardo, J. Marshall Haynie, Sreenath Sharma, Osamu Tagao, Nabeel Bardeesy, Masaya Takahashi, Jeff Settleman, Kwok Kin Wong, Diego H. Castrillon

Research output: Contribution to journalArticlepeer-review

80 Scopus citations

Fingerprint Dive into the research topics of 'Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds